Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul:196:135-137.
doi: 10.1016/j.puhe.2021.05.030. Epub 2021 Jun 2.

Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign

A Vallée  1 , A Chan-Hew-Wai  2 , B Bonan  2 , P Lesprit  3 , F Parquin  4 , É Catherinot  5 , J Choucair  5 , D Billard  6 , C Amiel-Taieb  7 , È Camps  2 , C Cerf  8 , D Zucman  9 , E Fourn  9
Affiliations

Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign

A Vallée et al. Public Health. 2021 Jul.

Abstract

Objectives: A strong COVID-19 vaccine campaign is needed to reach the herd immunity and reduce this pandemic infection.

Study design: In the Foch Hospital, France, in February 2021, 451 healthcare workers were vaccinated by a first dose of AstraZeneca vaccine.

Methods: Adverse effects were reported to our pharmaco-vigilance circuit, by an online and anonymous questionnaire following the first weeks of the vaccinal campaign to healthcare workers.

Results: Two hundred seventy-four (60.8%) of them reported multiple adverse effects. Main adverse effects reported were feverish state/chills (65.7%), fatigue/physical discomfort (62.4%), arthralgia/muscle pain (61.0%) and fever (44.5%).

Conclusions: On March 2021 many European countries suspended AstraZeneca vaccine for one week due to safety uncertainty. Thus, confidence in its efficacy is undermined. However, the benefit/risk balance is clearly in favor of vaccination.

Keywords: Adverse effects; AstraZeneca vaccine; COVID-19; COVID-19 vaccine; Vaccine campaign.

PubMed Disclaimer

References

    1. Fontanet A., Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020 Oct;20(10):583–584. - PMC - PubMed
    1. Voysey M., Costa Clemens S.A., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet Lond Engl. 2021 Feb 19, 6;397(10277):881–891. - PMC - PubMed
    1. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007 Apr;44(2):62–69. - PMC - PubMed
    1. PINHO AC . European Medicines Agency; 2021. COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine's benefits currently still outweigh risks Update [Internet]https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-inve... [cited 2021 Mar 29]. Available from:
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl. 2021 Jan 9;397(10269):99–111. - PMC - PubMed

Substances